Search results for "Caliche"

showing 3 items of 3 documents

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or…

2008

Abstract Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized CD22 antibody, conjugated to calicheamicin, a potent cytotoxic antitumor agent. Inotuzumab ozogamicin targets B-cell malignancies since they often express CD22. In a previously reported phase 1 dose-escalation trial in patients with CD22-positive B-cell non-Hodgkin’s lymphoma (NHL), the maximum tolerated dose (MTD) was determined to be 1.8 mg/m2 every 4 weeks. Responses were seen in patients with both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This ongoing study consisted of a limited dose escalation (DE) portion to confirm the MTD of inotuzumab ozogamicin whe…

Inotuzumab ozogamicinmedicine.medical_specialtybusiness.industryImmunologyFollicular lymphomaCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationchemistry.chemical_compoundchemistryhemic and lymphatic diseasesInternal medicineCalicheamicinmedicineRituximabbusinessDiffuse large B-cell lymphomaSurvival ratemedicine.drugBlood
researchProduct

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: resul…

2013

Purpose Inotuzumab ozogamicin (INO) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. We performed a phase I/II study to determine the maximum-tolerated dose (MTD), safety, efficacy, and pharmacokinetics of INO plus rituximab (R-INO) for treatment of relapsed/refractory CD20+/CD22+ B-cell non-Hodgkin lymphoma (NHL). Patients and Methods A dose-escalation phase to determine the MTD of R-INO was followed by an expanded cohort to further evaluate the efficacy and safety at the MTD. Patients with relapsed follicular lymphoma (FL), relapsed diffuse large B-cell lymphoma (DLBCL), or refractory aggressive NH…

OncologyAdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyNeutropeniamedicine.medical_treatmentFollicular lymphomaPharmacologyAntibodies Monoclonal HumanizedDrug Administration Schedulechemistry.chemical_compoundAntibodies Monoclonal Murine-Derivedimmune system diseasesRecurrenceRisk Factorshemic and lymphatic diseasesInternal medicineCalicheamicinAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInotuzumab OzogamicinMolecular Targeted TherapyB-cell lymphomaAgedHyperbilirubinemiaInotuzumab ozogamicinChemotherapybusiness.industryLymphoma Non-HodgkinMiddle Agedmedicine.diseasePrognosisThrombocytopeniaPolatuzumab vedotinLymphomaTreatment OutcomeOncologychemistryLiverRituximabFemalebusinessRituximabLiver Failuremedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Geomorphological west-east-section through the north chilean andes near antofagasta

2006

The extremely arid western slope of the Andes near Antofagasta is an area of young tectonic movements on the one hand, but of very low erosion rates on the other. Therefore the relief is characterized by very old erosional forms, but fresh and clearly visible tectonic forms. This is quite evident from the following characteristics of a west-east-section from the Coastal Cordillera to the High Cordillera: 1. The great height and steepness of the western escarpment of the Coastal Cordillera, devoid of deep valleys. 2. The preservation of the miocene and pliocene caliche deposits with highly soluble nitrates in the eastern part of the Coastal Cordillera and of the landforms covered by them. 3.…

PaleontologyTectonicsgeographyTectonic subsidencegeography.geographical_feature_categoryLandformSection (archaeology)ErosionCalicheEscarpmentAridGeology
researchProduct